US department of defense injects US$2.9M to Ischemix for its phase one trial of traumatic brain injury drug

US – Ischemix, a privately owned company focused on developing therapeutics for serious medical conditions, has received funding worth US$2.9M from the US department of defense (USDoD) to conduct its phase 1 study of a traumatic brain injury (TBI) drug. This fund was granted by US Army Medical Research and Development Command (USAMRDC), Combat Casualty Care Research Program (CCCRP) in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium. The funding is meant pay for a substantial portion of manufacturing and formulating additional supply of the…

Read More